Effective induction therapy with subcutaneous administration of bortezomib for newly diagnosed POEMS syndrome: a case report and a review of the literature.

Abstract

POEMS syndrome is characterized by polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin changes. Bortezomib is an important component of the chemotherapy regimen associated with multiple myeloma, and has been previously applied to POEMS syndrome. We present a 56-year-old Chinese man who was given subcutaneous administration of bortezomib as part of the BDex (bortezomib-dexamethasone) regimen for his POEMS syndrome. The peripheral neuropathy and laboratory-test results of the patient improved dramatically with 4 cycles of treatment, resulting in a complete response. In addition, the treatment was well tolerated and adequate peripheral blood hematopoietic stem cells were collected for an ensuing autologous stem cell transplant.

• Authors: Ke Zeng, Jin-rong Yang, Jun Li, Qing Wei, Yi-ming Yang, Ting Liu, Ting Niu
• Journal: Acta haematologica (Acta Haematol) Vol. 129 Issue 2 Pg. 101-5 ( 2013) ISSN: 1421-9662 [Electronic] Switzerland
• PMID: 23171959 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't, Review)
• Copyright: Copyright © 2012 S. Karger AG, Basel.

Chemical References

• Boronic Acids
• Pyrazines
• Bortezomib
• Dexamethasone

Topics

• Administration, Oral
• Boronic Acids (administration & dosage)
• Bortezomib
• Dexamethasone (administration & dosage)
• Humans
• Injections, Subcutaneous
• Male
• Middle Aged
• Neoadjuvant Therapy
• POEMS Syndrome (drug therapy)
• Pyrazines (administration & dosage)
• Remission Induction